Published in Cytokine Growth Factor Rev on February 01, 2002
The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology (2005) 3.18
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood (2003) 2.82
Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood (2007) 1.64
Brx mediates the response of lymphocytes to osmotic stress through the activation of NFAT5. Sci Signal (2009) 1.30
The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys (2008) 1.23
Susceptibility genes in the pathogenesis of murine lupus. Arthritis Res (2002) 1.00
Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte functions. Cytokine Growth Factor Rev (2013) 0.88
Systemic lupus erythematosus and increased risk to develop B cell malignancies: role of the p200-family proteins. Immunol Lett (2010) 0.86
Interferon-gamma-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis. Clin Exp Immunol (2004) 0.84
Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin. Leukemia (2012) 0.83
Serum levels of B-cell activating factor in chronic hepatitis B virus infection: association with clinical diseases. J Interferon Cytokine Res (2014) 0.80
B Cell-Activating Factor Regulates Different Aspects of B Cell Functionality and Is Produced by a Subset of Splenic B Cells in Teleost Fish. Front Immunol (2017) 0.75
Ultraviolet-A1 irradiation therapy for systemic lupus erythematosus. Lupus (2017) 0.75
AID is required for c-myc/IgH chromosome translocations in vivo. Cell (2004) 3.89
Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol (2009) 2.70
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res (2006) 1.99
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood (2005) 1.84
Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. Cancer Cell (2012) 1.40
NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells. J Immunol (2003) 1.38
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res (2008) 1.38
Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res (2005) 1.33
Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. Proc Natl Acad Sci U S A (2004) 1.21
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol (2007) 1.21
Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res (2008) 1.19
CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells. Immunity (2002) 1.18
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol (2008) 1.14
MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clin Cancer Res (2011) 1.14
Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood (2012) 1.11
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol (2010) 1.10
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. Cell Cycle (2013) 0.98
Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer Immun (2010) 0.97
Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood (2003) 0.97
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer (2010) 0.96
Luteinizing hormone-releasing hormone enhances T cell recovery following allogeneic bone marrow transplantation. J Immunol (2009) 0.93
Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors. Blood (2010) 0.90
TRAIL/Apo-2 ligand induces primary plasma cell apoptosis. J Immunol (2002) 0.89
Novel RNA regulatory mechanisms revealed in the epitranscriptome. RNA Biol (2013) 0.86
CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells. J Immunol (2009) 0.83
Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma. Crit Rev Oncol Hematol (2013) 0.82
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization. Clin Cancer Res (2013) 0.81
Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 0.79
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood (2013) 0.79
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. Leuk Lymphoma (2014) 0.78
Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc (2010) 0.75